

COM

the same ability to bind to TNF as the recombinant TNF binding protein set forth in claim 19.--

REMARKS

New claims 31-35 above are copied verbatim from (and thus correspond exactly to) claims 1, 7, 8, 11, and 12 of U.S. Patent No. 5,512,544, granted April 30, 1996, to David Wallach et al. (the '544 patent). To the extent that the '544 patent claims that are directed to recombinant protein are construed to encompass the amino acid sequences set forth in the references set forth at column 2, lines 40 to 45, of the '544 patent, new claims 36 to 39 correspond substantially to claims 1, 8, 11, and 12 of the '544 patent. Applicants file these new claims for the purpose of initiating an interference between claims 31 to 39 of this application and U.S. Patent No. 5,512,544.

If there are any fees due in connection with the filing of Preliminary Amendment, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an

extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:



M. Paul Barker
Reg. No. 32,013

Dated: April 29, 1997

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000